Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT04944914 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Camrelizumab Plus Stereotactic Body Radiotherapy vs Camrelizumab Alone For Oligometastatic Nasopharyngeal Carcinoma

Name: Camrelizumab Plus Stereotactic Body Radiotherapy vs Camrelizumab Alone For Oligometastatic Nasopharyngeal Carcinoma — clinical trial record (NCT04944914)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

StatusRecruiting

PhasePhase 3

SponsorSun Yat-sen University

Started2021-06-01

View on ClinicalTrials.gov ↗

Amendment history

2026-04-24

Study Status, Sponsor/Collaborators, Contacts/Locations v1

Primary completion date2024-06-01→2027-06-01

Completion date2026-06-01→2028-06-01

2021-06-28

Original filing

Sun Yat-sen University

609 trials monitored

See 13 trials at risk

Head & Neck Cancer

2,051 trials monitored

See 116 trials at risk

We intend to compare the efficacy and safety of immunotherapy plus stereotactic body radiotherapy at oligometastatic lesions and immunotherapy alone among patients with oligometastatic nasopharyngeal carcinoma whose primary lesion has been well controlled after radical local-regional treatment through this multicenter randomized phase 3 trial.

Trial Details

NCT Number	NCT04944914
Lead Sponsor	Sun Yat-sen University Collaborators: Affiliated Cancer Hospital & Institute of Guangzhou Medical University, Zhongshan People's Hospital, Guangdong, China, Guangdong Provincial People's Hospital
Conditions	Nasopharyngeal Carcinoma
Enrollment	188 participants
Start Date	2021-06-01
Primary Completion	2027-06-01 (estimated)
Study Completion	2028-06-01 (estimated)
Updated on ClinicalTrials.gov	2026-04-30